Cancer Stem Cell News Volume 3.38 | Oct 1 2014

    Cancer Stem Cell News 3.38 October 1, 2014

    Cancer Stem Cell News

         In this issue: Publications | Reviews | Science News | Industry News | Policy News | Events | Jobs
    Cell Therapy News on Facebook  CSCN on Twitter

    Intracellular Autofluorescence: A Biomarker for Epithelial Cancer Stem Cells
    Researchers identified and characterized an intrinsic autofluorescent phenotype in cancer stem cells of diverse epithelial cancers and used this marker to isolate and characterize these cells. [Nat Methods]
    Abstract | Press Release
    Culture Human Glioma-Derived Tumorspheres with NeuroCult™ - View Publications

    PUBLICATIONS (Ranked by impact factor of the journal)
    A Breast Cancer Stem Cell Niche Supported by Juxtacrine Signaling from Monocytes and Macrophages
    Researchers show that tumor-associated monocytes and macrophages create a cancer stem cell (CSC) niche through juxtacrine signaling with CSCs. [Nat Cell Biol] Abstract

    ​Sphingosine-1-Phosphate Promotes Expansion of Cancer Stem Cells via ​S1PR3 by a Ligand-Independent Notch Activation
    Using microarray screening in aldehyde dehydrogenase (ALDH)-positive cancer stem cell (CSC) model, scientists identified a fundamental role for a lipid mediator ​sphingosine-1-phosphate (​S1P) in CSC expansion. Stimulation with ​S1P enhanced ALDH-positive CSCs via ​S1P receptor 3 (​S1PR3) and subsequent Notch activation. [Nat Commun] Abstract

    Targeting Cancer Stem-Like Cells as an Approach to Defeating Cellular Heterogeneity in Ewing’s Sarcoma
    Researchers assessed the effect of combining a drug that abrogates cancer stem-like cell (CSC) properties with standard-of-care therapy in a Ewing sarcoma family tumor (ESFT). Primary ESFT from four patients containing CD133+ CSC subpopulations ranging from 3-17% of total tumor cells were subjected to treatment with enoxacin, doxorubicin or both drugs. [Cancer Res] Abstract

    p53 Protein Aggregation Promotes Platinum Resistance in Ovarian Cancer
    Investigators demonstrate that in a unique population of high-grade serous ovarian carcinoma cancer cells with cancer stem cell properties, p53 protein aggregation is associated with p53 inactivation and platinum resistance. [Oncogene] Abstract

    Annexin A3 as a Potential Target for Immunotherapy of Liver Cancer Stem-Like Cells
    Overexpression of Annexin A3 (ANXA3) increased the proportion of CD133+ cells, enhancing their tumorigenicity. On the contrary, knockdown of ANXA3 decreased CD133+ cells and inhibited tumorigenicity. The mechanistic study revealed that ANXA3-mediated maintenance of hepatocellular carcinoma cancer stem-like cell/cancer initiating cell activity was likely involved with the HIF1A/Notch pathway. [Stem Cells] Abstract

    Significance of Glioma-Associated Oncogene Homolog 1 (GLI1) Expression in Claudin-Low Breast Cancer and Crosstalk with the Nuclear Factor Kappa-Light-Chain-Enhancer of Activated B Cells (NFκB) Pathway
    High GLI1 expression is a property of claudin-low cells and tumors and correlates with markers of epithelial to mesenchymal transition and breast cancer stem cells. Knockdown of GLI1 expression in claudin-low cell lines resulted in reduced cell viability, motility, clonogenicity, self-renewal, and reduced tumor growth of orthotopic xenografts. [Breast Cancer Res] Abstract | Full Article

    Curcumin Suppresses Crosstalk between Colon Cancer Stem Cells and Stromal Fibroblasts in the Tumor Microenvironment: Potential Role of EMT
    Scientists investigated the crosstalk between colorectal cancer cells with stromal fibroblasts and the anti-cancer effects of curcumin and 5-Fluorouracil, especially on cancer stem cell survival in a 3D-co-culture model that mimics in vivo tumor microenvironment. [PLoS One] Full Article

    Cancer Stem-Like Sphere Cells Induced from De-Differentiated Hepatocellular Carcinoma-Derived Cell Lines Possess the Resistance to Anti-Cancer Drugs
    Investigators induced cancer stem-like cells from hepatocellular carcinoma cell lines using a unique medium, and examined their potential for resistance to anti-cancer drugs. [BMC Cancer] Abstract | Full Article

    NeuroCult™ for Brain Tumor Research - View Publications

    Emerging from the Shade of p53 Mutants: N-Terminally Truncated Variants of the p53 Family in EMT Signaling and Cancer Progression
    The prevailing view has been that N-terminally truncated p53 family isoforms predominantly counteract cell cycle arrest and apoptosis. Molecular connections between N-terminally truncated p53 family isoforms and self-renewal have arisen, suggesting their potential function in the generation of cancer stem cells from bulk tumor cells. [Sci Signal] Abstract

    Visit our reviews page to see a complete list of reviews in the cancer stem cell research field.

    Seattle Genetics and Takeda Announce Positive Data from Phase III AETHERA Clinical Trial of ADCETRIS® (Brentuximab Vedotin) for Consolidation in Post-Transplant Hodgkin Lymphoma
    Seattle Genetics, Inc. and Takeda Pharmaceutical Company Limited announced that patients with Hodgkin lymphoma who received ADCETRIS as consolidation therapy immediately following an autologous stem cell transplantation lived significantly longer without disease progression compared to patients who received placebo. [Seattle Genetics, Inc.] Press Release

    Transgene Presents Additional Positive Clinical Data from Phase IIb Part of TIME Trial with TG4010
    Transgene SA announced the presentation of more mature data from the Phase IIb part of the TIME trial with TG4010 MUC1 targeted immunotherapy. [Press release from Transgene SA discussing research presented at the European Society for Medical Oncology (ESMO) 2014 Congress, Madrid] Press Release | Poster

    From our sponsor: Free mouse hematopoietic progenitors wallchart. Request your copy.

    $7 Million Clinical Research Grant a Big Win for All New Mexicans
    The University of New Mexico Cancer Center won a five-year $7 million grant from the National Cancer Institute’s National Community Oncology Research Program (NCORP). The NCORP grant will strengthen and expand the clinical trials network in New Mexico. [University of New Mexico Cancer Center] Press Release

    Montefiore and Einstein Receive $3.4 Million NIH Grant for Cancer Clinical Trials
    Montefiore Einstein Center for Cancer Care and Albert Einstein College of Medicine of Yeshiva University have been awarded a $3.4 million grant from the National Cancer Institute to conduct multi-site cancer clinical trials and research focused on reducing healthcare disparities in cancer care. [Montefiore Medical Center] Press Release

    Four Researchers Awarded Grants to Investigate Effectiveness of Nintedanib in Lung, Colorectal, and Gastrointestinal Cancers
    The National Comprehensive Cancer Network® Oncology Research Program has awarded four grants to investigators to evaluate and define the clinical effectiveness of the investigational compound nintedanib in non-small cell lung, colorectal, and gastrointestinal cancers. [The National Comprehensive Cancer Network®] Press Release

    Nintedanib Receives Positive CHMP Opinion for Second-Line Treatment of Patients with Adenocarcinoma of the Lung
    Boehringer Ingelheim announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has issued a positive opinion for the approval of nintedanib in combination with docetaxel for the treatment of adult patients with locally advanced, metastatic or locally recurrent non-small cell lung cancer of adenocarcinoma tumor histology after first-line chemotherapy. [Boehringer Ingelheim GmbH] Press Release

    National Institutes of Health (United States)

    Food and Drug Administration (United States)

    Center for Biologics Evaluation and Research (United States)

    European Medicines Agency (European Union)

    Medicines and Healthcare Products Regulatory Agency (United Kingdom)

    Therapeutic Goods Administration (Australia)

    NEW Translational Cancer Research for Basic Scientists Workshop
    October 26-31, 2014
    Boston, United States

    Visit our events page to see a complete list of events in the cancer stem cell community.

    NEW Postdoctoral Position – Leukemic Stem Cells (BC Cancer Agency)

    NEW Assistant or Associate Professor – Cancer Biology (University of Pennsylvania)

    NEW Senior Research Scientist – DNA Damage Response and Genome Instability (International Clinical Research Center)

    Faculty Positions – Stem Cells and Regenerative Medicine (Baylor College of Medicine)

    Research Assistant or Research Associate – Stem Cell & Cancer Biology (University of North Texas Health Science Center)

    Postdoctoral Fellow – Stem Cells and Breast Cancer (Albert Einstein College of Medicine in New York)

    Assistant Professor – Cell, Developmental & Cancer Biology (Oregon Health & Science University)

    Postdoctoral Position – Cancer Biology (Yale University School of Medicine)

    Tenure Track Positions – Cancer Biology (Wake Forest Baptist Medical Center)

    Scientist – Pluripotent Stem Cell Media Development, High Throughput Screening (STEMCELL Technologies Inc.)

    Scientist – Cell Culture Support Products (STEMCELL Technologies Inc.)

    Scientist – Immunology/Cell Separation (STEMCELL Technologies Inc.)

    Recruit Top Talent: Reach more than 50,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.


    Have we missed an important article or publication in Cancer Stem Cell News? Click here to submit!

    Comments or suggestions? Submit your feedback here

    Learn more about Cancer Stem Cell News: Archives | Events | Contact Us